EGFR mutations in gefitinib first-line therapy for advanced NSCLC good effect

Inoue at the Japanese from June 2004 to October 2005 to conduct a clinical study showed II , and there never chemotherapy epidermal growth factor receptor (EGFR) gene mutations in advanced non-small cell lung cancer (NSCLC C) patients, gefitinib better efficacy, toxicity was tolerable. [J Clin Oncol 2006, 24 (21) : 3340] researchers examined 75 patients with advanced non-small cell lung cancer EGFR state 25 patients (33%) EGFR mutations exist. This is not chemotherapy in 25 patients. Of these, 16 patients received gefitinib therapy (250 mg per day), 9 patients received conventional chemotherapy. The median follow-up time of 7.6 months. Receive gefitinib treatment remission rate and disease control rate was 75% and 88% respectively. The median survival is no progress (PFS) was 9.7 months. The PFS received conventional chemotherapy for 7.6 months. Gefitinib treatment serious adverse events did not occur. Researchers believe EGFR mutation is used for first-line treatment with gefitinib for a higher response rate and longer PFS. Source : Medical Tribune